These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17333190)

  • 1. Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma.
    Cummings J; Ranson M; Butt F; Moore D; Dive C
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):921-4. PubMed ID: 17333190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.
    Linder S; Olofsson MH; Herrmann R; Ulukaya E
    Expert Rev Mol Diagn; 2010 Apr; 10(3):353-9. PubMed ID: 20370591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors.
    Ozturk B; Coskun U; Sancak B; Yaman E; Buyukberber S; Benekli M
    Int Immunopharmacol; 2009 May; 9(5):645-8. PubMed ID: 19249390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?
    Bilici A; Ustaalioglu BB; Ercan S; Orcun A; Seker M; Salepci T; Gumus M
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):309-16. PubMed ID: 20967544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of the β-expectation tolerance interval to method validation of the M30 and M65 ELISA cell death biomarker assays.
    Cummings J; Zhou C; Dive C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Apr; 879(13-14):887-93. PubMed ID: 21450541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer.
    de Haas EC; di Pietro A; Simpson KL; Meijer C; Suurmeijer AJ; Lancashire LJ; Cummings J; de Jong S; de Vries EG; Dive C; Gietema JA
    Neoplasia; 2008 Oct; 10(10):1041-8. PubMed ID: 18813353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarker.
    Olofsson MH; Cummings J; Fayad W; Brnjic S; Herrmann R; Berndtsson M; Hodgkinson C; Dean E; Odedra R; Wilkinson RW; Mundt KE; Busk M; Dive C; Linder S
    Cancer Biomark; 2009; 5(3):117-25. PubMed ID: 19407366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients.
    Ausch C; Buxhofer-Ausch V; Olszewski U; Hinterberger W; Ogris E; Schiessel R; Hamilton G
    Eur J Surg Oncol; 2009 Nov; 35(11):1164-8. PubMed ID: 19254831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity.
    Cummings J; Hodgkinson C; Odedra R; Sini P; Heaton SP; Mundt KE; Ward TH; Wilkinson RW; Growcott J; Hughes A; Dive C
    Mol Cancer Ther; 2008 Mar; 7(3):455-63. PubMed ID: 18347133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.
    Cummings J; Ranson M; Lacasse E; Ganganagari JR; St-Jean M; Jayson G; Durkin J; Dive C
    Br J Cancer; 2006 Jul; 95(1):42-8. PubMed ID: 16804528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival.
    Ulukaya E; Yilmaztepe A; Akgoz S; Linder S; Karadag M
    Lung Cancer; 2007 Jun; 56(3):399-404. PubMed ID: 17316892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimisation of circulating biomarkers of cell death for routine clinical use.
    Greystoke A; Cummings J; Ward T; Simpson K; Renehan A; Butt F; Moore D; Gietema J; Blackhall F; Ranson M; Hughes A; Dive C
    Ann Oncol; 2008 May; 19(5):990-5. PubMed ID: 18304966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of serum M30 and M65 levels in melanoma.
    Tas F; Karabulut S; Serilmez M; Yildiz I; Sen F; Ciftci R; Duranyildiz D
    Melanoma Res; 2013 Oct; 23(5):390-5. PubMed ID: 23812330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of serum M30 and M65 levels in patients with breast cancer.
    Tas F; Karabulut S; Yildiz I; Duranyildiz D
    Biomed Pharmacother; 2014 Oct; 68(8):1135-40. PubMed ID: 25465151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon alpha: possible use as a surrogate marker.
    Fisher MB; Zhang XQ; McConkey DJ; Benedict WF
    Cancer Gene Ther; 2009 Jul; 16(7):567-72. PubMed ID: 19197325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial.
    Cummings J; Zweifel M; Smith N; Ross P; Peters J; Rustin G; Price P; Middleton MR; Ward T; Dive C
    Br J Cancer; 2012 May; 106(11):1766-71. PubMed ID: 22538971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokeratin 18 as a Novel Biomarker in Patients with Hypertrophic Cardiomyopathy.
    Fragkiadakis K; Ktena N; Kalantidou A; Dermitzaki E; Anastasiou I; Papathanassiou S; Kontaraki J; Kalomoirakis P; Kanoupakis E; Patrianakos A; Papadomanolakis A; Daskalaki E; Kiousi T; Kouraki K; Kranioti E; Tzardi M; Venihaki M; Karagogeos D; Capetanaki Y; Kardassis D; Kochiadakis G; Parthenakis F; Marketou M
    Cells; 2024 Aug; 13(16):. PubMed ID: 39195218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum cytokeratin 18 as a biomarker for gastric cancer.
    Oyama K; Fushida S; Kinoshita J; Okamoto K; Makino I; Nakamura K; Hayashi H; Inokuchi M; Nakagawara H; Tajima H; Fujita H; Takamura H; Ninomiya I; Kitagawa H; Fujimura T; Ohta T
    Clin Exp Med; 2013 Nov; 13(4):289-95. PubMed ID: 22825587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell Death and Prognosis of Mortality in Alcoholic Hepatitis Patients Using Plasma Keratin-18.
    Woolbright BL; Bridges BW; Dunn W; Olson JC; Weinman SA; Jaeschke H
    Gene Expr; 2017 Nov; 17(4):301-312. PubMed ID: 28770701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers.
    Langer F; Chun FK; Amirkhosravi A; Friedrich M; Leuenroth S; Eifrig B; Bokemeyer C; Francis JL
    Thromb Haemost; 2007 Mar; 97(3):464-70. PubMed ID: 17334515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.